LAU-7b featured in The Pharmaceutical Journal among next-generation antivirals targeting COVID-19
LAU-7b featured in The Pharmaceutical Journal (The Royal Pharmaceutical Society) among next-generation antivirals targeting COVID-19
Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022
LAU-7b first inflammation-controlling drug to demonstrate clinical benefit in adults with CF, complementary to administration of CFTR modulators.Study achieves clinically meaningful reduction in lung function loss at 6 months, measured…
Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19…